Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedMar 10, 2026
DataAggregated Company Financials
Companies1395
  • 7D-2.5%
  • 3M1.0%
  • 1Y6.5%
  • YTD-2.1%

Over the last 7 days, the Healthcare industry has dropped 2.5%, and Johnson & Johnson contributed the most with a 2.4% decline. Over the past 12 months, the industry was up 6.5%. Earnings are forecast to grow by 16% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 10 Mar 2026US$6.4tUS$3.3tUS$125.9b25.5x50.5x1.9x
Thu, 05 Feb 2026US$6.5tUS$3.2tUS$126.3b26.9x51.2x2x
Sat, 03 Jan 2026US$6.5tUS$3.2tUS$135.6b25.7x47.8x2x
Mon, 01 Dec 2025US$6.5tUS$3.2tUS$133.5b26.5x48.9x2.1x
Wed, 29 Oct 2025US$6.1tUS$3.1tUS$140.4b26x43.5x2x
Fri, 26 Sep 2025US$5.7tUS$3.1tUS$137.6b23.1x41.4x1.8x
Sun, 24 Aug 2025US$5.7tUS$3.1tUS$137.2b23.7x41.8x1.9x
Tue, 22 Jul 2025US$5.4tUS$3.0tUS$128.7b22.6x42x1.8x
Thu, 19 Jun 2025US$5.5tUS$3.0tUS$127.5b22.8x42.9x1.8x
Sat, 17 May 2025US$5.3tUS$3.0tUS$126.1b23.3x42.1x1.7x
Mon, 14 Apr 2025US$5.3tUS$2.6tUS$82.2b24.9x64.6x2x
Wed, 12 Mar 2025US$5.7tUS$2.6tUS$79.0b26.5x72.5x2.2x
Fri, 07 Feb 2025US$6.0tUS$2.6tUS$90.6b26.9x66x2.3x
Sun, 05 Jan 2025US$5.8tUS$2.9tUS$79.3b27.3x73.5x2x
Tue, 03 Dec 2024US$6.2tUS$2.9tUS$77.4b28.7x79.7x2.1x
Thu, 31 Oct 2024US$6.1tUS$2.8tUS$66.8b27.7x90.6x2.1x
Sat, 28 Sep 2024US$6.2tUS$2.8tUS$60.1b30.1x103.5x2.2x
Mon, 26 Aug 2024US$6.3tUS$2.8tUS$56.4b31.6x111.1x2.2x
Wed, 24 Jul 2024US$6.3tUS$2.8tUS$60.8b31.9x104.1x2.2x
Fri, 21 Jun 2024US$6.2tUS$2.8tUS$62.5b30x98.5x2.2x
Sun, 19 May 2024US$6.2tUS$2.8tUS$64.1b31.1x97.2x2.2x
Tue, 16 Apr 2024US$6.0tUS$2.8tUS$85.3b31.1x70.1x2.1x
Thu, 14 Mar 2024US$6.3tUS$2.8tUS$84.4b32.4x74.6x2.3x
Sat, 10 Feb 2024US$6.2tUS$2.8tUS$76.6b31.5x80.7x2.2x
Mon, 08 Jan 2024US$6.3tUS$2.8tUS$90.0b30.9x70.1x2.2x
Wed, 06 Dec 2023US$6.0tUS$2.8tUS$91.4b29x65.2x2.1x
Fri, 03 Nov 2023US$5.6tUS$2.8tUS$90.6b25.8x62x2x
Sun, 01 Oct 2023US$5.9tUS$2.8tUS$98.2b27.6x59.7x2.1x
Tue, 29 Aug 2023US$6.1tUS$2.8tUS$99.0b27.7x61.6x2.2x
Thu, 27 Jul 2023US$6.1tUS$2.7tUS$113.1b27.5x54.1x2.2x
Sat, 24 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.8x2.2x
Mon, 22 May 2023US$6.0tUS$2.7tUS$110.8b24.2x53.9x2.2x
Wed, 19 Apr 2023US$6.0tUS$2.5tUS$118.4b24.5x50.3x2.4x
Fri, 17 Mar 2023US$5.7tUS$2.5tUS$122.4b23.8x46.5x2.3x
Price to Earnings Ratio

46.5x


Total Market Cap: US$5.7tTotal Earnings: US$122.4bTotal Revenue: US$2.5tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 50.5x which is lower than its 3-year average PE of 65.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-1.50%
Healthcare-2.51%
Healthtech4.61%
Biotech-1.19%
Life Sciences-1.67%
Pharma-2.23%
Healthcare Services-3.61%
Medical Equipment-4.20%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 56.1x.
    • Analysts are expecting annual earnings growth of 16.1%, which is higher than its past year's earnings growth of 6.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 50% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HCA HCA HealthcareUS$545.132.3%
+US$2.7b		62.2%PE18x
VEEV Veeva SystemsUS$195.577.8%
+US$2.3b		-18.4%PE35.4x
XENE Xenon PharmaceuticalsUS$62.7647.5%
+US$1.7b		83.2%PS696.1x
HIMS Hims & Hers HealthUS$22.1634.5%
+US$1.3b		-35.7%PE39.3x
MRNA ModernaUS$55.745.5%
+US$1.1b		55.0%PS11.3x

Latest News

DNTH
US$79.23
Dianthus Therapeutics
7D
43.4%
1Y
225.5%
XENE
US$62.76
Xenon Pharmaceuticals
7D
47.5%
1Y
83.2%
SYK
US$365.92
Stryker
7D
-5.5%
1Y
-1.1%
ABBV
US$227.45
AbbVie
7D
-2.9%
1Y
5.0%
HCA
US$545.13
HCA Healthcare
7D
2.3%
1Y
62.2%
HIMS
US$22.16
Hims & Hers Health
7D
34.5%
1Y
-35.7%
BSX
US$71.90
Boston Scientific
7D
-5.7%
1Y
-23.6%
LLY
US$1,008.39
Eli Lilly
7D
-0.9%
1Y
21.5%

LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning

The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.
MDT
US$91.34
Medtronic
7D
-6.9%
1Y
-2.6%
MRK
US$117.11
Merck
7D
-3.5%
1Y
23.0%
JNJ
US$242.59
Johnson & Johnson
7D
-2.4%
1Y
44.7%
ROIV
US$29.53
Roivant Sciences
7D
5.1%
1Y
179.1%

ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout Upside

Analysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.
VEEV
US$195.57
Veeva Systems
7D
7.8%
1Y
-18.4%
DAWN
US$21.33
Day One Biopharmaceuticals
7D
105.7%
1Y
164.3%
MRNA
US$55.74
Moderna
7D
5.5%
1Y
55.0%
UNH
US$285.17
UnitedHealth Group
7D
-3.3%
1Y
-40.6%

UNH: Medicare Advantage Reset And Rebate Actions Will Support Multi-Year Earnings Recovery

Our updated view trims UnitedHealth Group's fair value estimate to $364.63 from $392.24 as analysts factor in softer revenue growth assumptions, a slightly higher discount rate, and modestly lower long term profit expectations following a broad wave of reduced Street price targets on the stock. Analyst Commentary Street research on UnitedHealth has turned more cautious in the near term, with a cluster of lower price targets from multiple firms and a smaller group of more constructive views.